The TB Alliance conducted a phase two clinical trial aimed at developing and testing a new drug regimen for MDR-TB patients called BPaMZ, which consists of four oral drugs: bedquiline, pretomanid, moxifloxican and pyrazinamide. Over an eight-week period, patients treated with the new BPaMZ regimen cleared M. tuberculosis bacteria from their sputum up to 3.5 times faster than patients who received standard treatments. “The next step is to do a phase three trial, on about 1,200 patients – if we have positive results from that we can apply for regulatory approval from authorities,” stated the TB Alliance’s Dr. Christo van Niekerk.
The TB Alliance presented its findings from the BPaMZ trial at the Conference on Retroviruses and Opportunistic Infections that took place in Seattle in February.
Read more about the trial and next steps here.